Back to Journals » Cancer Management and Research » Volume 13

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]

Authors Li X, Chen W, Liu K, Zhang S, Yang R, Liu K, Li D, Huang Y

Received 9 March 2021

Accepted for publication 9 March 2021

Published 16 March 2021 Volume 2021:13 Pages 2515—2516

DOI https://doi.org/10.2147/CMAR.S310256


Li X, Chen W, Liu K, et al. Cancer Manag Res. 2020;12:8081–8091

The authors have advised Figure 5D and 5E (on page 8088) is incorrect due to layout negligence during figure disposal. The correct Figure is shown below.


Read the original article

Li X, Chen W, Liu K, et al. Cancer Manag Res. 2020;12:8081–8091

The authors have advised Figure 5D and 5E (on page 8088) is incorrect due to layout negligence during figure disposal. The correct Figure is shown below:

Figure 5 The Akt pathway played an important role in the anticancer effect of combined oridonin and sorafenib treatment. (A) SC79 was used to enhance the phosphorylation of Akt after cotreatment with oridonin and sorafenib, which partially restored the levels of proteins associated with proliferation, apoptosis and EMT. (B) Colony formation assays showed that SC79 treatment restored the proliferation that was inhibited by combined oridonin and sorafenib treatment. (C) Flow cytometry showed that the enhanced apoptosis induction caused by combined oridonin and sorafenib treatment was mitigated by SC79 treatment. (D and E) Reactivation of AKT after SC79 treatment restored cell migration and invasion that had been impaired by cotreatment with the two drugs. (The data represent the mean ± SD of three independent experiments. *Indicates p<0.05 compared with the combination group; Ori + Sor indicates combined oridonin and sorafenib treatment).

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]